Microbiological Diagnosis and Antibiotic Therapy in Patients with Community-Acquired Pneumonia and Acute COPD Exacerbation in Daily Clinical Practice: Comparison to Current Guidelines
- First Online:
The aim of this secondary analysis was to evaluate current microbiological approaches, microbiology, and antibiotic therapy in patients with community-acquired pneumonia (CAP) and acute exacerbation of chronic obstructive pulmonary disease (AECOPD) in clinical practice and to compare them with current international guidelines.
A total of 362 patients with suspected CAP were enrolled in 14 European centers in a prospective multicenter study.
A total of 279 inpatients (CAP, n = 222; AECOPD, n = 57) were evaluated. A total of 83 (37 %) CAP patients and 25 (44 %) AECOPD patients did not undergo any microbiological tests. In patients with CAP/AECOPD, blood culture was performed in 109 (49 %)/16 (28.1 %), urinary antigen tests for Legionella pneumophila in 67 (30 %)/9 (16 %), and sputum investigation in 55 (25 %)/17 (30 %), respectively. The most frequent pathogens in CAP were Streptococcus pneumoniae, Mycoplasma pneumoniae, Chlamydia pneumoniae, L. pneumophila, Staphylococcus aureus, and Enterobacter cloacae; in AECOPD they were Escherichia coli, Haemophilus haemolyticus, Haemophilus influenzae, and Moraxella catarrhalis. All CAP patients (mean = 11.1 days) and 35 (61.4 %) of AECOPD patients (mean = 8.9 days) received antibiotics. CAP patients were given mostly aminopenicillin with β-lactamase inhibitors and AECOPD patients were given mostly cephalosporins.
Pathogens isolated in CAP and AECOPD and the antibiotic therapy used are in good accordance with the guidelines. Blood culture, recommended for all CAP patients, was performed in only 50 % of the cases and antibiotic therapy lasted longer than the suggested 5–7 days. Therefore, international guidelines regarding performance of blood culture and duration of antibiotic therapy should be adopted more often. This duration was independent of the number of isolated pathogens and number of symptoms on admission. Therefore, the question arises as to whether microbiological data are necessary only for patients who are resistant to initial therapy.
KeywordsCommunity-acquired pneumonia Microbiological diagnosis Antibiotic therapy Guidelines Acute exacerbation of chronic obstructive pulmonary disease
Acute exacerbation of chronic obstructive pulmonary disease
American thoracic society
British thoracic society
Chronic obstructive pulmonary disease
European respiratory society
Infectious disease society of America
Lower respiratory tract infection
Polymerase chain reaction
- 1.Woodhead M, Blasi F, Ewig S, Garau J, Huchon G, Ieven M et al (2011) Joint task force of the European respiratory society and European society for clinical microbiology and infectious diseases. Guidelines for the management of adult lower respiratory tract infections—full version. Clin Microbiol Infect 17(Suppl 6):1–59PubMedCrossRefGoogle Scholar
- 2.Höffken G, Lorenz J, Kern W, Welte T, Bauer T, Dalhoff K et al (2009) Epidemiology, diagnosis, antimicrobial therapy and management of community-acquired pneumonia and lower respiratory tract infections in adults. Guidelines of the Paul-Ehrlich-Society for Chemotherapy, the German Respiratory Society, the German Society for Infectiology and the competence network CAPNETZ Germany. Pneumologie 63:e1–e68PubMedCrossRefGoogle Scholar
- 3.Global strategy for the diagnosis, management, and prevention of chronic obstuctive pulmonary disease. www.goldcopd.org. Accessed Feb 2013
- 5.National Institute for Health and Care Excellence, National Clinical Guideline Centre, Chronic Obstructive Pulmonary Disease (2010) Management of chronic obstructive pulmonary disease in adults in primary and secondary care (CG101). http://guidance.nice.org.uk/CG101
- 6.Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC et al (2007) Infectious diseases society of America; American thoracic society (2007) Infectious diseases society of America/American thoracic society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 44(Suppl 2):S27–S72PubMedCrossRefGoogle Scholar
- 7.Celli BR, MacNee W, ATS/ERS Task Force (2004) Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 23:932–946Google Scholar
- 9.National Committee for Clinical Laboratory Standards (2004) Performance standards for antimicrobial susceptibility testing, 14th informational supplement. Approved standard M100-S14. Wayne, PA: National Committee for Clinical Laboratory StandardsGoogle Scholar